The authors noticed that although several therapeutic options were considered including remdesivir, tocilizumab, or immune globulin, infliximab has been chosen because of the potential positive outcome of a TNF-α blockade in both Crohn’s disease and cytokine storm associated with PIMS-TS/MIS-C [22]. The gene discussed is TNF; the disease is Crohn disease.